If a pharmaceutical company develops a new drug that acts as an agonist to a G-protein coupled receptor (GPCR) in pancreatic beta cells, which consequence follows?

💡 Explanation

GPCR agonists enhance receptor signaling, leading to increased intracellular signaling cascades that stimulate insulin release. Because activation of the receptor amplifies the normal insulin production pathway, insulin secretion increases; rather than decreasing glucagon, affecting glycogenolysis, or directly upregulating GLUT4 in muscle.

• If a patient with hypocalcemia experiences sustained muscle contraction (tetany), why does the skeletal muscle remain contracted, preventing relaxation?
• Which mechanism explains why repeated drug use leads to decreased sensitivity in the mesolimbic reward circuit?
• As individuals age, and mitochondrial function declines, which consequence follows regarding the impact of reactive oxygen species (ROS) on musculoskeletal health?
• Why does chronic B12 deficiency lead to neurological damage in the dorsal columns of the spinal cord, rather than primarily affecting motor neurons?
• Why does tolerance to opioids, leading to increased dosage requirements in pain management, develop within the neural circuit?
• If a previously vaccinated individual encounters an antigen years later, which process explains why the secondary immune response is faster and more effective?